Evidence map›Paper›PMID 40924301›Full record

ArticleEndocrine2025

Glycated albumin as a diagnostic tool for diabetes mellitus in transfusion-dependent β-thalassemia patients.

Gianluca Marzi, Martina Verrienti, Filomena Longo, Camilla Alice Cattaneo, Alberto Gobbo, Katalin Vetralla, Gian Pietro Franzè, Alberto Cossu, Martina Culcasi, Maria Chiara Zatelli and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gianluca MarziSection of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Martina VerrientiUnit of Endocrinology and Metabolic Diseases, Department of Specialty Medicine, Azienda Ospedaliero Universitaria S.Anna, Ferrara, Italy.
Filomena LongoDay Hospital of Thalassemia and Hemoglobinopathies, Department of Specialty Medicine, Azienda Ospedaliero Universitaria S. Anna, Ferrara, Italy.
Camilla Alice CattaneoUnit of Endocrinology and Metabolic Diseases, Department of Specialty Medicine, Azienda Ospedaliero Universitaria S.Anna, Ferrara, Italy.
Alberto GobboSection of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Katalin VetrallaSection of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Gian Pietro FranzèIntegrated Activity Department, Imaging and Laboratory Diagnostics, Clinical Pathology, Azienda Ospedaliero Universitaria S. Anna, Ferrara, Italy.
Alberto CossuRadiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Martina CulcasiDay Hospital of Thalassemia and Hemoglobinopathies, Department of Specialty Medicine, Azienda Ospedaliero Universitaria S. Anna, Ferrara, Italy.
Maria Chiara ZatelliSection of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Maria Rosaria AmbrosioSection of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy. mbrmrs@unife.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionβ-thalassemia is an inherited hemoglobinopathy which, in severe cases, requires lifelong transfusions, leading to iron overload and increases risk of metabolic complications, including diabetes mellitus. The standard glycemic marker, glycated hemoglobin, is unreliable in transfusion-dependent patients due to altered erythrocyte turnover. This study investigates the possible utility of glycated albumin as an alternative biomarker for diagnosing glucose metabolism disorders in transfusion-dependent patients.

methodsA cross-sectional analysis was conducted on 254 transfusion-dependent patients followed at the Center for Hemoglobinopathies and Thalassemia at Ferrara Hospital, evaluating Glycated Albumin levels, fasting plasma glucose, oral glucose tolerance test results, and iron overload assessed by Magnetic Resonance Imaging.

resultsGlycated Albumin levels significantly correlated with Fasting Plasma Glucose (r = 0.710, p < 0.01), Oral Glucose Tolerance Test glucose levels at 60 and 120 min, and the area under the glycemic curve (p < 0.01). ROC curve analysis identified a Glycated Albumin cutoff of 14.95% for Diabetes Mellitus diagnosis, with a sensitivity of 93.1% and specificity of 89.1%. Glycated Albumin correlated with hepatic and heart iron accumulation but not with pancreatic iron overload.

conclusionsThese findings indicate Glycated Albumin as a promising marker for glycemic assessment in transfusion-dependent patients, warranting further validation in multicenter studies.

Indexed as

beta-ThalassemiaDiabetes MellitusSerum AlbuminAdolescentAdultBiomarkersBlood GlucoseBlood TransfusionCross-Sectional StudiesFemaleGlucose Tolerance TestGlycated Serum AlbuminGlycation End Products, AdvancedHumansIron OverloadMaleBiomarkersBlood GlucoseGlycated Serum AlbuminGlycation End Products, AdvancedSerum AlbuminBeta thalassemiaDiabetesGlycated albuminIron overloadTransfusion

Identifiers

PMID40924301
PMCPMC12708767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.